Clinical cancer advances 2016: Annual report on progress against cancer from the American society of clinical oncology

Journal of Clinical Oncology

Volumn 34, Issue 9, 2016, Pages 987-1011

  Dizon, Don S ^a   Krilov, Lada ^c   Cohen, Ezra ^d   Gangadhar, Tara ^g   Ganz, Patricia A ^e   Hensing, Thomas A ⁱ   Hunger, Stephen ^h   Krishnamurthi, Smitha S ^j   Lassman, Andrew B ^a   Markham, Merry Jennifer ⁿ   Mayer, Erica ^b   Neuss, Michael ^p   Pal, Sumanta Kumar ^f   Richardson, Lisa C ^q   Schilsky, Richard ^c   Schwartz, Gary K ^k   Spriggs, David R ^l   Villalona Calero, Miguel Angel ^o   Villani, Gina ^m   Masters, Gregory ^r  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

^k Columbia University ^*  (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m Ralph Lauren Center for Cancer Care and Prevention   (United States)

ⁿ UNIVERSITY OF FLORIDA   (United States)

^o MIAMI CANCER INSTITUTE   (United States)

^p VANDERBILT INGRAM CANCER CENTER   (United States)

^q CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^r HELEN F GRAHAM CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CONFERENCE PAPER; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MEDICAL SOCIETY; MELANOMA; ONCOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; ECONOMICS; FINANCIAL MANAGEMENT; NEOPLASMS; PROCEDURES; TRENDS;

FINANCING, GOVERNMENT; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84962050675     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.8427     Document Type: Conference Paper

References (88)

1. American Cancer Society: Cancer Facts & Figures 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf
2. Rahib L, Smith BD, Aizenberg R, et al: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74: 2913-2921, 2014
3. Henley SJ, Singh SD, King J, et al: Centers for Disease Control and Prevention (CDC): Invasive cancer incidence and survival: United States, 2011. MMWR Morb Mortal Wkly Rep 64: 237-242, 2015
4. American Cancer Society: Cancer Treatment & Survivorship Facts & Figures (2014-2015). http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042801.pdf
5. Robert C, Schachter J, Long GV, et al.; KEYNOTE-006 investigators: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521-2532, 2015
6. US Food and Drug Administration: FDA approves Opdivo for advanced melanoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm
7. Weber JS, D'Angelo SP, Minor D, et al: Nivo-lumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384, 2015
8. Postow MA, Chesney J, Pavlick AC, et al: Nivo-lumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372: 2006-2017, 2015
9. US Food and Drug Administration: Nivolumab in combination with ipilimumab. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm
10. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N EnglJ Med 373: 23-34, 2015
11. US Food and Drug Administration: FDA expands approved use of Opdivo to treat lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm
12. Brahmer J, Reckamp KL, Baas P, et al: Nivo-lumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015
13. Paz-Ares L, Horn L, Borghael H, et al: Phase III, randomized trial (CheckMate 057) of nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer. J Clin Oncol 33, 2015 (suppl; abstr LBA109)
14. US Food and Drug Administration: FDA expands approved use of Opdivo in advanced lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm
15. Gettinger SN, Horn L, Gandhi L, et al: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33: 2004-2012, 2015
16. Garon EB, Rizvi NA, Hui R, et al.; KEYNOTE-001 Investigators: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018-2028, 2015
17. US Food and Drug Administration: FDA approves Keytruda for advanced non-small cell lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm
18. Rizvi N, Garon E, Patnaik A, et al: Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 32: 507s, 2014 (suppl; abstr 800)
19. Gettinger S, Shepherd F, Antonia S, et al: Firstline nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 32: 512s, 2014 (suppl; abstr 8024)
20. Vansteenkiste J, Fehrenbacher L, Spira AI, et al: Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Presented at the European Cancer Congress, Vienna, Austria, September 25-29, 2015 (abstr 14LBA)
21. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558-562, 2014
22. Motzer RJ, Rini BI, McDermott DF, et al: Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 33: 1430-1437, 2015
23. Motzer RJ, Escudier B, McDermott DF, et al.; CheckMate 025 Investigators: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1803-1813, 2015
24. US Food and Drug Administration: FDA approves Opdivo to treat advanced form of kidney cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm
25. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx
26. El-Khoueiry AB, Melero I, Crocenzi TS, et al: Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 33, 2015 (suppl; abstr LBA101)
27. Seiwert TY, Haddad RI, Gupta S, et al: Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol 33, 2015 (suppl; abstr LBA6008)
28. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372: 311-319, 2015
29. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520, 2015
30. Topp MS, Gökbuget N, Stein AS, et al: Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lympho-blastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol 16: 57-66, 2015
31. US Food and Drug Administration: FDA approves Blincyto to treat a rare form of acute lymphoblastic leukemia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425549.htm
32. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371: 1507-1517, 2014
33. Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33: 540-549, 2015
34. Reardon DA, Schuster J, Tran DD, et al: ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J Clin Oncol 33, 2015 (suppl; abstr 2009)
35. de Martel C, Ferlay J, Franceschi S, et al: Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 13: 607-615, 2012
36. US Food and Drug Administration: FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm
37. Joura EA, Giuliano AR, Iversen OE, et al: Broad Spectrum HPV Vaccine Study: A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372: 711-723, 2015
38. Saraiya M, Unger ER, Thompson TD, et al.; HPV Typing of Cancers Workgroup: US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 107: djv086, 2015
39. Reagan-Steiner S, Yankey D, Jeyarajah J, et al: National, regional, state, and selected local area vaccination coverageamong adolescents aged 13-17 years: United States, 2014. MMWR Morb Mortal Wkly Rep 64: 784-792, 2015
40. Stupp R, Taillibert S, Kanner A, et al: Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma - First report of the full dataset of the EF14 randomized phase III trial. J Clin Oncol 33, 2015 (suppl; abstr 2000)
41. US Food and Drug Administration: NovoTTF-100A System: P100034. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm254480.htm
42. US Food and Drug Administration: FDA approves expanded indication for medical device to treat a form of brain cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465744.htm
43. Francis PA, Regan MM, Fleming GF, et al.; SOFT Investigators; International Breast Cancer Study Group: Adjuvant ovarian suppression in pre-menopausal breast cancer. N Engl J Med 372: 436-446, 2015
44. Margolese R, Cecchini RS, Julian TB, et al: Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. J Clin Oncol 33, 2015 (suppl; abstr LBA500)
45. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311: 1998-2006, 2014
46. Ou SH, Ahn J, De Petris L, et al: Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer patients who have failed prior crizotinib: An open-label single-arm, global phase II study. J Clin Oncol 33, 2015 (suppl; abstr 8008)
47. US Food and Drug Administration: FDA approves new oral therapy to treat ALK-positive lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm
48. Awad MM, Shaw AT: ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 12: 429-439, 2014
49. Shaw AT, Ou SH, Bang YJ, et al: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371: 1963-1971, 2014
50. Drilon A, Sima C, Somwar R, et al: Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. J Clin Oncol 33, 2015 (suppl; abstr 8007)
51. Planchard D, Groen HJ, Kim T, et al: Interim results of a phase II study of BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in patients with BRAFV600E mutated metastatic non-small-cell lung cancer. J Clin Oncol 33, 2015 (suppl; abstr 8006)
52. Frampton GM, Ali SM, Rosenzweig M, et al: Comprehensive genomic profiling of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors. J Clin Oncol 33, 2015 (suppl; abstr 11007)
53. Treon SP, Tripsas CK, Meid K, et al: Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 372: 1430-1440, 2015
54. US Food and Drug Administration: FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432123.htm
55. Röllig C, Müller-Tidow C, Hüttmann A, et al: Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: Results from 267 patients treated in the randomized placebo-controlled SAL-Soraml Trial. Presented at the 2014 American Society for Hematology Annual Meeting, December 7, 2014 (abstr 6)
56. US Food and Drug Administration: FDA approves Lynparza to treat advanced ovarian cancer. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm427554.htm?source=govdelivery&utm-medium=email&utm-source=govdelivery
57. Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15: 852-861, 2014
58. Oza AM, Cibula D, Benzaquen AO, et al: Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncol 16: 87-97, 2015
59. Liu JF, Barry WT, Birrer M, et al: Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study. Lancet Oncol 15: 1207-1214, 2014
60. Ledermann JA, Perren TJ, Raja FA, et al: Randomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum-sensitive ovarian cancer: Results of the ICON6 trial. Presented at the European Cancer Congress, Amsterdam, Netherlands, September 30, 2013 (abstr 10)
61. McNeish IA, Oza AM, Robert L, et al: Results of ARIEL2: A phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol 33, 2015 (suppl; abstr 5508)
62. Patch AM, Christie EL, Etemadmoghadam D, et al.; Australian Ovarian Cancer Study Group: Whole-genome characterization of chemoresistant ovarian cancer. Nature 521: 489-494, 2015
63. Finn RS, Crown JP, Lang I, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 16: 25-35, 2015
64. US Food and Drug Administration: FDA approves Ibrance for postmenopausal women with advanced breast cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm
65. Turner NC, Ro J, André F, et al: PALOMA3 Study Group: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373: 209-219, 2015
66. Choueiri TK, Escudier B, Powles T, et al.; METEOR Investigators: Cabozantinib versus ever-olimus in advanced renal-cell carcinoma. N Engl J Med 373: 1814-1823, 2015
67. Noh SH, Park SR, Yang H-K, et al.; CLASSIC trial investigators: Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15: 1389-1396, 2014
68. Schöffski P, Maki RG, Italiano A, et al: Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 33, 2015 (suppl; abstr LBA10502)
69. Demetri GD, von Mehren M, Jones RL, et al: A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). J Clin Oncol 33, 2015 (suppl; abstr 10503)
70. US Food and Drug Administration: FDA approves new therapy for certain types of advanced soft tissue sarcoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468832.htm
71. D'Cruz AK, Vaish R, Kapre N, et al.; Head and Neck Disease Management Group: Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373: 521-529, 2015
72. Mehanna HM, Wong WL, McConkey CC, et al: PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT). J Clin Oncol 33, 2015 (suppl; abstr 6009)
73. Bonjer HJ, Deijen CL, Abis GA, et al.; COLOR II Study Group: A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 372: 1324-1332, 2015
74. Chagpar AB, Killelea BK, Tsangaris TN, et al: A randomized, controlled trial of cavity shave margins in breast cancer. N Engl J Med 373: 503-510, 2015
75. Whelan TJ, Olivotto IA, Parulekar WR, et al.; MA.20 Study Investigators: Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373: 307-316, 2015
76. Poortmans PM, Collette S, Kirkove C, et al.; EORTC Radiation Oncology and Breast Cancer Groups: Internal mammary and medial supra-clavicular irradiation in breast cancer. N Engl J Med 373: 317-327, 2015
77. Armstrong GT, Yasui Y, Chen Y, et al: Reduction in late mortality among 5-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol 33, 2015 (suppl; abstr LBA2)
78. Peters C, Schrappe M, von Stackelberg A, et al: Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors - The ALL-SCT-BFM-2003 trial. J Clin Oncol 33: 1265-1274, 2015
79. Fouad M, Acemgil A, Bae S, et al: Patient navigation as a model to increase minority participation in cancer clinical trials. J Clin Oncol 33, 2015 (suppl; abstr 6559)
80. Brown PD, Asher AL, Ballman KV, et al: NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol 33, 2015 (suppl; abstr LBA4)
81. Aoyama H, Tago M, Shirato H; Japanese Radiation Oncology Study Group 99-1 (JROSG 99-1) Investigators: Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: Secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 1: 457-464, 2015
82. Smith TJ, Temin S, Alesi ER, et al: American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care. J Clin Oncol 30: 880-887, 2012
83. Bakitas MA, Tosteson TD, Li Z, et al: Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33: 1438-1445, 2015
84. Dionne-Odom JN, Azuero A, Lyons KD, et al: Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: Outcomes from the ENABLE III randomized controlled trial. J Clin Oncol 33: 1446-1452, 2015
85. Obermeyer Z, Powers BW, Makar M, et al: Physician characteristics strongly predict patient enrollment in hospice. Health Aff (Millwood) 34: 993-1000, 2015
86. Stewart BW, Wild CP (eds): World Cancer Report 2014. Lyon, France, IARC Press, 2014
87. Thun MJ, DeLancey JO, Center MM, et al: The global burden of cancer: priorities for prevention. Carcinogenesis 31: 100-110, 2010
88. Smith BD, Smith GL, Hurria A, et al: Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 27: 2758-2765, 2009